Last updated on April 2019

Project: Every Child for Younger Patients With Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Central Nervous System Neoplasms | Childhood Immature Teratoma | Lymphoproliferative Disorder | Stromal Neoplasm | Childhood Mature Teratoma | Childhood Langerhans Cell Histiocytosis | Aggressive fibromatosis | Mesoblastic Nephroma | MYELOPROLIFERATIVE DISORDER | Childhood Malignant Neoplasm
  • Age: - 25 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem
  • Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority
  • Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
  • All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of two ?2? (carcinoma in situ) or three ?3? (malignant)
  • All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
  • The following other benign/borderline conditions:
  • Mesoblastic nephroma
  • Teratomas (mature and immature types)
  • Myeloproliferative diseases including transient myeloproliferative disease
  • Langerhans cell histiocytosis
  • Lymphoproliferative diseases
  • Desmoid tumors
  • Gonadal stromal cell tumors
  • Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit
  • All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission
  • If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.